{
    "code": "52027000",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027000",
    "time": "2018-07-20 03:54:33",
    "許可證字號": "衛部藥輸字第027000號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/02\/10",
    "發證日期": "106\/02\/10",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202700007",
    "中文品名": "捷抑炎持續性藥效錠11毫克",
    "英文品名": "Xeljanz XR Extended Release Tablets 11 mg",
    "適應症": "(1) 類風濕性關節炎：XELJANZ XR (tofacitinib) 適用於治療患有中至重度活動性類風濕性關節炎且對methotrexate無法產生適當治療反應或無法耐受methotrexate之成人病人。本品可用於單一療法或與methotrexate或其他非生物性的疾病緩解型抗風濕藥物 (DMARDs) 合併使用。\r\n(2) 乾癬性關節炎：XELJANZ XR (tofacitinib) 與非生物性的疾病緩解型抗風濕藥物 (DMARDs) 合併使用，適用於治療患有活動性乾癬性關節炎且對methotrexate或其他疾病緩解型抗風濕性藥物 (DMARDs) 無法產生適當治療反應或無法耐受之成人病人。\r\n使用限制：不建議XELJANZ XR 與生物性的疾病緩解型抗風濕性藥物 (DMARDs)，或與強效免疫抑制劑（如azathioprine與cyclosporine）合併使用。",
    "劑型": "121持續性藥效錠",
    "包裝": "2-1000粒塑膠瓶裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": [
        "Tofacitinibcitrate"
    ],
    "限制項目": "02輸　入 1D須執行風險管理計畫 1L監視中新藥",
    "申請商名稱": "1504402200  輝瑞大藥廠股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F370049000  PFIZER PHARMACEUTICALS LLC",
        "製造廠廠址": "RD. 2 KM 58.2, BARCELONETA, PUERTO RICO 00617",
        "製造廠公司地址": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "6605071926  久裕企業股份有限公司",
            "製造廠廠址": "桃園市桃園區大林里興邦路43巷2之1號4樓，3樓B區，1樓A區",
            "製造廠公司地址": "",
            "製造廠國別": "",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        },
        {
            "製造廠名稱": "F370019000  PFIZER PHARMACEUTICALS LLC",
            "製造廠廠址": "KM. 1.9 ROAD 689, VEGA BAJA, PUERTO RICO 00693",
            "製造廠公司地址": "",
            "製造廠國別": "PUERTO RICO",
            "製程": "包裝"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200080610",
            "成分名稱": "Tofacitinib citrate",
            "含量描述": "",
            "含量": "17.7710000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Xeljanz XR-INS-070502-107-05-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027000&Seq=003&Type=9"
        },
        {
            "title": "Xeljanz XR Tablets 11mg 30s-Lab-060221-106-03-07.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027000&Seq=002&Type=8"
        },
        {
            "title": "Xeljanz XR Tablets 11mg 14s-Lab-060221-106-03-07.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027000&Seq=001&Type=8"
        }
    ]
}